APOMAB Detects Tumor Responses to Chemotherapy
Author Information
Author(s): Al-Ejeh Fares, Darby Jocelyn M., Tsopelas Chris, Smyth Douglas, Manavis Jim, Brown Michael P.
Primary Institution: Hanson Institute, Adelaide, South Australia, Australia
Hypothesis
Can APOMAB® effectively image tumor responses to DNA-damaging chemotherapy?
Conclusion
The radiolabeled La-specific monoclonal antibody, DAB4, can detect dead tumor cells after chemotherapy, indicating its potential for imaging responses to cancer therapy.
Supporting Evidence
- APOMAB® binds preferentially to apoptotic tumor cells after chemotherapy.
- Increased tumor accumulation of DAB4 correlates with extended survival in treated mice.
- Immunohistochemical analysis shows significant caspase-3 activation and PARP-1 cleavage post-chemotherapy.
- Radiolabeled DAB4 can differentiate between dead tumor cells and normal tissues.
Takeaway
This study shows that a special antibody can find dead cancer cells after treatment, which might help doctors see if the treatment is working.
Methodology
The study used a syngeneic EL4 lymphoma model in mice to assess the accumulation of Indium 111-labeled DAB4 after chemotherapy, measuring tumor cell apoptosis through immunohistochemical analysis.
Limitations
The study was conducted in a mouse model, which may not fully replicate human responses to chemotherapy.
Participant Demographics
C57BL/6 mice, 6–8 weeks old
Statistical Information
P-Value
p<0.001
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website